brimonidine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihypertensives, clonidine derivatives 395 59803-98-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • UK 14,304
  • mirvaso
  • brimonidine
  • brimonidine tartrate
  • bromoxidine
A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
  • Molecular weight: 292.14
  • Formula: C11H10BrN5
  • CLOGP: 1.49
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 62.20
  • ALOGS: -3.28
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1.50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Sept. 6, 1996 FDA
March 25, 2020 PMDA Senju Pharmaceutical Co., Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eye irritation 686.56 17.10 230 12129 16384 46657319
Intraocular pressure increased 666.12 17.10 178 12181 5779 46667924
Treatment failure 656.40 17.10 368 11991 92719 46580984
Ocular hyperaemia 655.68 17.10 232 12127 19478 46654225
Eye pain 374.54 17.10 171 12188 27769 46645934
Eye pruritus 225.31 17.10 93 12266 11805 46661898
Vision blurred 204.61 17.10 169 12190 79539 46594164
Glaucoma 193.10 17.10 91 12268 15830 46657873
Foreign body sensation in eyes 149.40 17.10 43 12316 1833 46671870
Product delivery mechanism issue 117.77 17.10 25 12334 289 46673414
Dry eye 116.81 17.10 82 12277 30240 46643463
Erythema of eyelid 114.76 17.10 35 12324 1826 46671877
Iridocyclitis 112.27 17.10 35 12324 1965 46671738
Visual acuity reduced 112.21 17.10 71 12288 22042 46651661
Inappropriate schedule of product administration 111.61 17.10 110 12249 64903 46608800
Uveitis 103.53 17.10 49 12310 8592 46665111
Hypersensitivity 96.09 17.10 155 12204 150166 46523537
Eye swelling 90.80 17.10 60 12299 20043 46653660
Visual impairment 86.17 17.10 97 12262 66592 46607111
Corneal oedema 80.77 17.10 26 12333 1620 46672083
Lacrimation increased 80.64 17.10 51 12308 15810 46657893
Eye discharge 78.20 17.10 34 12325 4894 46668809
Conjunctivitis 76.93 17.10 49 12310 15375 46658328
Eye allergy 74.38 17.10 19 12340 512 46673191
Product packaging quantity issue 72.61 17.10 22 12337 1122 46672581
Ocular surface disease 71.54 17.10 12 12347 31 46673672
Rebound effect 71.54 17.10 27 12332 2700 46671003
Scleral hyperaemia 70.02 17.10 16 12343 265 46673438
Corneal opacity 68.85 17.10 19 12340 693 46673010
Product container issue 66.68 17.10 23 12336 1776 46671927
Eyelid irritation 65.30 17.10 16 12343 362 46673341
Open angle glaucoma 64.37 17.10 15 12344 272 46673431
Dry mouth 57.86 17.10 72 12287 54854 46618849
Conjunctival hyperaemia 56.95 17.10 21 12338 1968 46671735
Conjunctivitis allergic 54.84 17.10 16 12343 715 46672988
Cataract 53.48 17.10 63 12296 45352 46628351
Erythema 53.23 17.10 117 12242 142703 46531000
Product quality issue 51.47 17.10 55 12304 35593 46638110
Corneal disorder 48.83 17.10 18 12341 1685 46672018
Eye disorder 47.53 17.10 39 12320 18102 46655601
Iris adhesions 47.27 17.10 12 12347 315 46673388
Eyelid margin crusting 47.08 17.10 14 12345 669 46673034
Intraocular pressure decreased 46.91 17.10 10 12349 118 46673585
Eye inflammation 46.85 17.10 22 12337 3787 46669916
Vitreous haemorrhage 43.86 17.10 17 12342 1827 46671876
Skin burning sensation 39.03 17.10 28 12331 10664 46663039
Intraocular pressure test abnormal 39 17.10 9 12350 156 46673547
Ocular discomfort 38.78 17.10 18 12341 3017 46670686
Conjunctival follicles 37.54 17.10 6 12353 10 46673693
Corneal neovascularisation 36.47 17.10 8 12351 109 46673594
Cystoid macular oedema 35.96 17.10 14 12345 1522 46672181
Photophobia 35.47 17.10 30 12329 14514 46659189
Eyelids pruritus 35.30 17.10 11 12348 616 46673087
Blindness 34.87 17.10 32 12327 17237 46656466
Abnormal sensation in eye 34.44 17.10 14 12345 1704 46671999
Intraocular pressure fluctuation 33.98 17.10 6 12353 23 46673680
Punctate keratitis 31.54 17.10 10 12349 593 46673110
Blepharitis 30.98 17.10 14 12345 2207 46671496
Eyelid oedema 30.83 17.10 24 12335 10333 46663370
Product physical consistency issue 29.64 17.10 9 12350 462 46673241
Hypothermia 29.44 17.10 25 12334 12158 46661545
Hypotonia 28.78 17.10 21 12338 8208 46665495
Swelling of eyelid 28.39 17.10 11 12348 1180 46672523
Dizziness 28.28 17.10 170 12189 340244 46333459
Rosacea 27.94 17.10 15 12344 3426 46670277
Ocular pemphigoid 26.76 17.10 5 12354 28 46673675
Blindness unilateral 26.65 17.10 17 12342 5340 46668363
Product packaging issue 26.62 17.10 10 12349 986 46672717
Choroidal effusion 26.06 17.10 8 12351 426 46673277
Keratic precipitates 25.48 17.10 6 12353 114 46673589
Eye colour change 25.35 17.10 7 12352 256 46673447
Angle closure glaucoma 25.22 17.10 12 12347 2127 46671576
Visual field defect 24.69 17.10 17 12342 6066 46667637
Bradycardia 24.29 17.10 54 12305 66244 46607459
Product storage error 24.10 17.10 22 12337 11770 46661933
Liquid product physical issue 23.52 17.10 8 12351 592 46673111
Macular oedema 22.89 17.10 14 12345 4087 46669616
Eyelash thickening 22.14 17.10 4 12355 18 46673685
Retinopathy haemorrhagic 21.96 17.10 4 12355 19 46673684
Eyelid disorder 21.37 17.10 9 12350 1197 46672506
Expired product administered 21.15 17.10 15 12344 5607 46668096
Eyelid pain 20.59 17.10 6 12353 267 46673436
Endocrine ophthalmopathy 20.42 17.10 6 12353 275 46673428
Meniscus injury 20.29 17.10 15 12344 5981 46667722
Retinal detachment 20.10 17.10 14 12345 5086 46668617
Chondropathy 20.06 17.10 10 12349 1960 46671743
Conjunctival oedema 19.84 17.10 7 12352 578 46673125
Deep anterior chamber of the eye 19.63 17.10 3 12356 3 46673700
Accidental exposure to product 19.61 17.10 26 12333 21055 46652648
Blood pressure decreased 19.21 17.10 45 12314 57114 46616589
Pain of skin 18.94 17.10 16 12343 7726 46665977
Foreign body in eye 18.93 17.10 5 12354 154 46673549
Product leakage 18.81 17.10 6 12353 363 46673340
Laryngeal stenosis 18.71 17.10 7 12352 683 46673020
Corneal infiltrates 18.54 17.10 5 12354 167 46673536
Pyrexia 18.16 17.10 41 12318 348761 46324942
Eye haemorrhage 18.13 17.10 15 12344 7037 46666666
Vitreous detachment 17.97 17.10 9 12350 1782 46671921
Product use complaint 17.87 17.10 9 12350 1803 46671900
Flat anterior chamber of eye 17.81 17.10 4 12355 61 46673642
Maternal exposure during pregnancy 17.56 17.10 3 12356 102546 46571157
Corneal deposits 17.44 17.10 5 12354 210 46673493
Overdose 17.43 17.10 3 12356 101976 46571727
Reaction to preservatives 17.41 17.10 5 12354 211 46673492
Small intestinal haemorrhage 17.35 17.10 9 12350 1917 46671786

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Treatment failure 605.74 17.87 265 8765 34414 29909034
Intraocular pressure increased 594.85 17.87 162 8868 4958 29938490
Ocular hyperaemia 407.30 17.87 138 8892 8905 29934543
Eye irritation 404.93 17.87 123 8907 5573 29937875
Eye pain 221.17 17.87 95 8935 11694 29931754
Visual acuity reduced 161.95 17.87 84 8946 15762 29927686
Vision blurred 161.38 17.87 119 8911 41697 29901751
Eye pruritus 161.32 17.87 56 8974 3871 29939577
Corneal oedema 149.77 17.87 41 8989 1271 29942177
Glaucoma 132.17 17.87 54 8976 5854 29937594
Foreign body sensation in eyes 110.76 17.87 27 9003 522 29942926
Ocular surface disease 105.53 17.87 19 9011 71 29943377
Choroidal detachment 99.83 17.87 23 9007 345 29943103
Visual impairment 94.10 17.87 76 8954 30362 29913086
Product delivery mechanism issue 91.98 17.87 18 9012 115 29943333
Hypotony of eye 85.65 17.87 17 9013 118 29943330
Lacrimation increased 79.79 17.87 40 8990 6976 29936472
Open angle glaucoma 76.04 17.87 17 9013 221 29943227
Blepharitis 72.52 17.87 22 9008 987 29942461
Corneal opacity 70.30 17.87 19 9011 560 29942888
Conjunctivitis 66.51 17.87 37 8993 7963 29935485
Uveitis 64.56 17.87 32 8998 5445 29938003
Conjunctivitis allergic 62.39 17.87 17 9013 517 29942931
Eye discharge 61.08 17.87 22 9008 1691 29941757
Erythema of eyelid 59.61 17.87 17 9013 613 29942835
Corneal disorder 59.58 17.87 18 9012 796 29942652
Scleral hyperaemia 59.00 17.87 11 9019 52 29943396
Intraocular pressure decreased 57.90 17.87 12 9018 106 29943342
Ocular discomfort 54.66 17.87 19 9011 1316 29942132
Blindness 54.18 17.87 38 8992 12271 29931177
Iridocyclitis 53.66 17.87 19 9011 1390 29942058
Corneal neovascularisation 53.17 17.87 10 9020 50 29943398
Cataract 52.06 17.87 47 8983 21788 29921660
Eye swelling 49.84 17.87 32 8998 8932 29934516
Eyelid margin crusting 49.63 17.87 11 9019 137 29943311
Accidental exposure to product 48.69 17.87 33 8997 10082 29933366
Choroidal effusion 48.31 17.87 11 9019 156 29943292
Product container issue 46.66 17.87 15 9015 815 29942633
Blindness unilateral 46.20 17.87 23 9007 3949 29939499
Punctate keratitis 45.76 17.87 12 9018 314 29943134
Cystoid macular oedema 45.25 17.87 14 9016 671 29942777
Conjunctival hyperaemia 41.58 17.87 18 9012 2249 29941199
Product packaging quantity issue 40.86 17.87 13 9017 683 29942765
Product quality issue 40.08 17.87 38 8992 18736 29924712
Hypersensitivity 38.63 17.87 63 8967 53965 29889483
Retinal detachment 38.26 17.87 22 9008 5038 29938410
Keratic precipitates 36.60 17.87 8 9022 93 29943355
Angle closure glaucoma 36.15 17.87 12 9018 722 29942726
Dry eye 35.73 17.87 23 9007 6445 29937003
Conjunctival follicles 35.54 17.87 5 9025 0 29943448
Rosacea 34.95 17.87 13 9017 1094 29942354
Eyelid irritation 33.55 17.87 7 9023 64 29943384
Inappropriate schedule of product administration 33.51 17.87 50 8980 39678 29903770
Visual field defect 32.78 17.87 19 9011 4417 29939031
Eyelids pruritus 32.30 17.87 7 9023 78 29943370
Eye allergy 32.25 17.87 6 9024 28 29943420
Eye infection 31.70 17.87 16 9014 2826 29940622
Reaction to preservatives 30.39 17.87 5 9025 9 29943439
Hyperaemia 29.06 17.87 11 9019 972 29942476
Liquid product physical issue 28.36 17.87 8 9022 277 29943171
Thunderclap headache 27.76 17.87 6 9024 66 29943382
Pyelitis 26.83 17.87 6 9024 78 29943370
Eye inflammation 26.79 17.87 12 9018 1625 29941823
Photophobia 25.63 17.87 18 9012 5818 29937630
Hyphaema 25.53 17.87 8 9022 400 29943048
Ulcerative keratitis 25.38 17.87 11 9019 1378 29942070
Anterior chamber inflammation 24.83 17.87 7 9023 242 29943206
Product dose omission issue 24.71 17.87 72 8958 91559 29851889
Visual acuity tests abnormal 23.13 17.87 5 9025 55 29943393
Incorrect dose administered 22.70 17.87 37 8993 31649 29911799
Flat anterior chamber of eye 22.43 17.87 5 9025 64 29943384
Abnormal sensation in eye 21.81 17.87 8 9022 647 29942801
Retinal haemorrhage 21.70 17.87 15 9015 4728 29938720
Corneal degeneration 21.62 17.87 4 9026 18 29943430
Keratitis interstitial 21.62 17.87 4 9026 18 29943430
Erythema 21.01 17.87 61 8969 77390 29866058
Corneal infiltrates 20.83 17.87 6 9024 224 29943224
Trabeculectomy 20.80 17.87 4 9026 23 29943425
Keratitis 20.59 17.87 9 9021 1151 29942297
Dizziness 20.48 17.87 114 8916 194795 29748653
Reversible cerebral vasoconstriction syndrome 20.41 17.87 6 9024 241 29943207
Instillation site pain 19.72 17.87 5 9025 114 29943334
Eyelid exfoliation 19.24 17.87 3 9027 3 29943445
Eye disorder 19.12 17.87 17 9013 7717 29935731
Vitreous floaters 19.07 17.87 12 9018 3232 29940216
Retinal disorder 18.62 17.87 8 9022 981 29942467
Corneal epithelium defect 18.61 17.87 6 9024 329 29943119
Eyelid oedema 18.61 17.87 14 9016 5031 29938417
Macular oedema 18.32 17.87 11 9019 2727 29940721
Neutropenia 18.18 17.87 8 9022 128532 29814916
Anterior chamber cell 17.90 17.87 6 9024 372 29943076

Pharmacologic Action:

SourceCodeDescription
ATC D11AX21 DERMATOLOGICALS
OTHER DERMATOLOGICAL PREPARATIONS
OTHER DERMATOLOGICAL PREPARATIONS
Other dermatologicals
ATC S01EA05 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Sympathomimetics in glaucoma therapy
ATC S01GA07 SENSORY ORGANS
OPHTHALMOLOGICALS
DECONGESTANTS AND ANTIALLERGICS
Sympathomimetics used as decongestants
FDA MoA N0000000209 Adrenergic alpha-Agonists
FDA EPC N0000175552 alpha-Adrenergic Agonist
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:35569 alpha-adrenergic receptor agonist
CHEBI has role CHEBI:35674 antihypertensive
CHEBI has role CHEBI:37886 adrenomimetics

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Ocular hypertension indication 4210003 DOID:9282
Open-angle glaucoma indication 84494001 DOID:1067
Rosacea indication 398909004 DOID:8881
Bronchospasm contraindication 4386001
Complete atrioventricular block contraindication 27885002
Orthostatic hypotension contraindication 28651003
Acute cerebrovascular insufficiency contraindication 29322000
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Anaphylaxis contraindication 39579001
Sinus bradycardia contraindication 49710005
General anesthesia contraindication 50697003
Thromboangiitis obliterans contraindication 52403007 DOID:12918
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Myasthenia gravis contraindication 91637004 DOID:437
Acute disease of cardiovascular system contraindication 128487001
Partial atrioventricular block contraindication 195039008
Decompensated cardiac failure contraindication 195111005
Hypoglycemic disorder contraindication 237630007
Raynaud's phenomenon contraindication 266261006
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.64 Basic
pKa2 1.82 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2B adrenergic receptor GPCR AGONIST EC50 7.26 WOMBAT-PK CHEMBL
Alpha-2A adrenergic receptor GPCR AGONIST EC50 8.39 WOMBAT-PK CHEMBL
Alpha-2C adrenergic receptor GPCR AGONIST EC50 8.47 WOMBAT-PK CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 5.55 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 5.27 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.84 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 6.07 DRUG MATRIX
Adrenergic receptor alpha-2 GPCR Ki 7.52 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 7.28 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 6.13 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.59 CHEMBL

External reference:

IDSource
E6GNX3HHTE UNII
D02076 KEGG_DRUG
70359-46-5 SECONDARY_CAS_RN
4021002 VANDF
4024043 VANDF
C0525227 UMLSCUI
CHEBI:3175 CHEBI
CHEMBL844 ChEMBL_ID
CHEMBL2062257 ChEMBL_ID
DB00484 DRUGBANK_ID
D000068438 MESH_DESCRIPTOR_UI
6863 INN_ID
2435 PUBCHEM_CID
520 IUPHAR_LIGAND_ID
134615 RXNORM
14807 MMSL
205316 MMSL
240890 MMSL
31659 MMSL
4297 MMSL
44062 MMSL
46686 MMSL
006196 NDDF
006197 NDDF
108827001 SNOMEDCT_US
372547000 SNOMEDCT_US
386924004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ALPHAGAN P HUMAN PRESCRIPTION DRUG LABEL 1 0023-9177 SOLUTION/ DROPS 1.50 mg OPHTHALMIC NDA 23 sections
COMBIGAN HUMAN PRESCRIPTION DRUG LABEL 2 0023-9211 SOLUTION/ DROPS 2 mg OPHTHALMIC NDA 26 sections
ALPHAGAN P HUMAN PRESCRIPTION DRUG LABEL 1 0023-9321 SOLUTION/ DROPS 1 mg OPHTHALMIC NDA 23 sections
SIMBRINZA HUMAN PRESCRIPTION DRUG LABEL 2 0065-4147 SUSPENSION/ DROPS 2 mg OPHTHALMIC NDA 24 sections
SIMBRINZA HUMAN PRESCRIPTION DRUG LABEL 2 0078-0904 SUSPENSION/ DROPS 2 mg OPHTHALMIC NDA 26 sections
Mirvaso HUMAN PRESCRIPTION DRUG LABEL 1 0299-5980 GEL 5 mg TOPICAL NDA 26 sections
Brimonidine Tartrate Human Prescription Drug Label 1 14445-400 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 24 sections
BRIMONIDINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-883 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 12 sections
Brimonidine HUMAN PRESCRIPTION DRUG LABEL 1 17478-715 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 25 sections
Brimonidine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 24208-411 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 22 sections
LUMIFY Redness Reliever Eye Drops HUMAN OTC DRUG LABEL 1 24208-537 SOLUTION/ DROPS 0.25 mg OPHTHALMIC NDA 13 sections
Brimonidine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 25685-715 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 12 sections
Brimonidine HUMAN PRESCRIPTION DRUG LABEL 1 50090-1046 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 24 sections
Brimonidine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-1800 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 22 sections
Brimonidine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-4224 SOLUTION 2 mg OPHTHALMIC ANDA 24 sections
ALPHAGAN P HUMAN PRESCRIPTION DRUG LABEL 1 54868-4276 SOLUTION/ DROPS 1 mg OPHTHALMIC NDA 25 sections
ALPHAGAN P HUMAN PRESCRIPTION DRUG LABEL 1 54868-4690 SOLUTION/ DROPS 1.50 mg OPHTHALMIC NDA 25 sections
Brimonidine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 54868-6094 SOLUTION 1.50 mg OPHTHALMIC NDA 10 sections
Brimonidine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 54868-6287 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 22 sections
COMBIGAN HUMAN PRESCRIPTION DRUG LABEL 2 54868-6295 SOLUTION/ DROPS 2 mg OPHTHALMIC NDA 23 sections
Brimonidine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 61314-143 SOLUTION 2 mg OPHTHALMIC ANDA 23 sections
Brimonidine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 61314-144 SOLUTION 1.50 mg OPHTHALMIC NDA 25 sections
BRIMONIDINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 70069-231 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 23 sections
BRIMONIDINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 70069-232 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 23 sections
BRIMONIDINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 70069-233 SOLUTION/ DROPS 2 mg OPHTHALMIC ANDA 23 sections
Brim-Dor PF HUMAN PRESCRIPTION DRUG LABEL 2 70261-518 SOLUTION/ DROPS 1.50 mg OPHTHALMIC unapproved drug other 2 sections
Tim-Brim-Dor PF HUMAN PRESCRIPTION DRUG LABEL 3 70261-520 SOLUTION/ DROPS 1.50 mg OPHTHALMIC unapproved drug other 2 sections
Tim-Brim-Dor-Lat HUMAN PRESCRIPTION DRUG LABEL 4 70261-522 SOLUTION/ DROPS 1.50 mg OPHTHALMIC unapproved drug other 2 sections
BRIMONIDINE TARTRATE 0.25% / POTASSIUM AZELOYL DIGLYCINULLTE 8% HUMAN PRESCRIPTION DRUG LABEL 1 72934-1027 GEL 0.25 g TOPICAL unapproved drug other 4 sections
BRIMONIDINE TARTRATE 0.25% / IVERMECTIN 1% / METRONIDAZOLE 1% / NIACINULLMIDE 4% HUMAN PRESCRIPTION DRUG LABEL 4 72934-1028 GEL 0.25 g TOPICAL unapproved drug other 4 sections